Dr. Salles on New Agents Being Investigated in Follicular Lymphoma

Video

Gilles Salles MD, PhD, Centre Hospitalier Lyon-Sud, discusses new agents being investigated for patients with follicular lymphoma.

Gilles Salles MD, PhD, Centre Hospitalier Lyon-Sud, discusses new agents being investigated for patients with follicular lymphoma.

PI3 kinase inhibitors are currently of interest in patients with follicular lymphoma who have failed prior therapy. A select group of patients will benefit from these drugs and the response generally lasts for 1 year.

A small portion of patients respond to BTK inhibitors, such as ibrutinib (Imbruvica), but only some of the responses are long lasting, explains Salles.

Additionally, immunotherapy has not had much activity as a single agent, but combinations are currently being investigated for patients with follicular lymphoma.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD